Mechanism of Action Remdesivir:
Remdesivir is a prodrug of an adenosine analog developed by Gilead Sciences, Inc. It acts as a RNA-dependent RNA polymerase (RdRp) inhibitor, targeting the viral genome replication process. After the host metabolizes remdesivir into active nucleoside triphosphate (NTP), the metabolite competes with adenosine triphosphate (ATP) for incorporation into the nascent RNA strand.[2] This unusual incorporation results in premature termination of RNA synthesis, halting the growth of the RNA strand after a few more nucleotides are added. Once remdesivir is added into the growing chain (i position), it cannot cause an immediate stop, rather it will continue to extend three more nucleotides down to pause the strand at (i+3) position.[3]